Skip to main content

Table 8 Summary of the incidence of adverse events

From: Orally active prostacyclin analogue beraprost sodium in patients with chronic kidney disease: a randomized, double-blind, placebo-controlled, phase II dose finding trial

Parameter

120 μg

240 μg

Placebo

Number of patients evaluated

36

41

35

Number of patients who experienced adverse events

27 (75.0 %)

36 (87.8 %)

28 (80.0 %)

Number of patients who experienced serious adverse events

3 (8.3 %)

4 (9.8 %)

1 (2.9 %)

Number of patients who discontinued the study treatment due to adverse events

4 (11.1 %)

7 (17.1 %)

0 (0.0 %)

Number of patients who interrupted the study treatment due to adverse events

0 (0.0 %)

2 (4.9 %)

0 (0.0 %)

  1. (): Incidence rate